

JosÃ© Antonio SacristÃ¡n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5889538/publications.pdf>

Version: 2024-02-01

48
papers

2,014
citations

361045

20
h-index

253896

43
g-index

67
all docs

67
docs citations

67
times ranked

2578
citing authors

#	ARTICLE	IF	CITATIONS
1	Individual point-of-care trials: a new approach to incorporate patientâ€™s preferences into personalized pragmatic clinical trials. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 152-155.	2.4	5
2	Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?. <i>Value in Health</i> , 2020, 23, 25-31.	0.1	7
3	How to assess the value of low-value care. <i>BMC Health Services Research</i> , 2020, 20, 1000.	0.9	7
4	El mÃ©dico frente a la COVID-19: lecciones de una pandemia. <i>Educacion Medica</i> , 2020, 21, 265-271.	0.3	5
5	Some reflections on the use of inappropriate comparators in CEA. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 29.	0.6	11
6	Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. <i>PLoS ONE</i> , 2020, 15, e0234705.	1.1	22
7	What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2020, 37, 1479-1495.	1.3	12
8	Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions. <i>Rheumatology and Therapy</i> , 2019, 6, 473-477.	1.1	2
9	Pragmatic trials revisited: applicability is about individualization. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 164-166.	2.4	12
10	Improving Health Care Value by Considering Cost-effectiveness. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1287.	3.8	2
11	Generalizability in Pragmatic Trials. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 87.	3.8	10
12	Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 491-495.	0.6	0
13	Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. <i>Patient Preference and Adherence</i> , 2016, 10, 1.	0.8	16
14	Patient involvement in clinical research: why, when, and how. <i>Patient Preference and Adherence</i> , 2016, 10, 631.	0.8	244
15	Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. <i>Advances in Therapy</i> , 2016, 33, 2059-2068.	1.3	8
16	On heterogeneity of treatment effects and clinical freedom. <i>International Journal of Clinical Practice</i> , 2015, 69, 6-8.	0.8	4
17	No big data without small data: learning health care systems begin and end with the individual patient. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 1014-1017.	0.9	44
18	Where is the person in precision medicine?. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 1022-1023.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Clinical research and medical care: towards effective and complete integration. BMC Medical Research Methodology, 2015, 15, 4.	1.4	49
20	Do new Cancer drugs offer good value for Money? the perspective of oncologists, payers, patients, and general Population. Clinical Therapeutics, 2015, 37, e18-e19.	1.1	0
21	Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison. BMC Psychiatry, 2014, 14, 298.	1.1	11
22	Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Medical Informatics and Decision Making, 2013, 13, 6.	1.5	190
23	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics, 2012, 3, 273.	1.1	23
24	Which Nontraditional Outcomes Should Be Measured in Healthcare Decision-Making in Schizophrenia? A Systematic Review. Perspectives in Psychiatric Care, 2012, 48, 198-207.	0.9	8
25	Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinología Y Nutrición (English Edition), 2011, 58, 331-340.	0.5	12
26	A Systematic Review of Patient-Reported and Economic Outcomes: Value to Stakeholders in the Decision-Making Process in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics, 2011, 33, 1225-1245.	1.1	26
27	Exploratory trials, confirmatory observations: A new reasoning model in the era of patient-centered medicine. BMC Medical Research Methodology, 2011, 11, 57.	1.4	13
28	Health economics: the start of clinical freedom. BMC Health Services Research, 2010, 10, 183.	0.9	6
29	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	3.8	10
30	Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España. Gaceta Sanitaria, 2004, 18, 50-57.	0.6	13
31	Problems and solutions in calculating quality-adjusted life years (QALYs). Health and Quality of Life Outcomes, 2003, 1, 80.	1.0	228
32	Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. European Neuropsychopharmacology, 2003, 13, 39-48.	0.3	17
33	Global index of safety (GIS). Journal of Clinical Epidemiology, 2001, 54, 1120-1125.	2.4	8
34	Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry, 2001, 1, 7.	1.1	35
35	"Dr. Sacristan and Colleagues Reply". Journal of Clinical Psychiatry, 2001, 62, 828-829.	1.1	0
36	Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. International Clinical Psychopharmacology, 2000, 15, 107-113.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study. <i>Clinical Therapeutics</i> , 2000, 22, 583-599.	1.1	47
38	Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients. <i>International Journal of Antimicrobial Agents</i> , 2000, 15, 65-71.	1.1	16
39	The Safety of Olanzapine Compared With Other Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 335-343.	1.1	63
40	SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study. <i>Journal of Affective Disorders</i> , 1999, 52, 111-119.	2.0	8
41	The Negative Side of Cost-effectiveness Analysis-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 1932.	3.8	1
42	Use of Salivary Caffeine Tests to Assess the Inducer Effect of a Drug on Hepatic Metabolism. <i>Annals of Pharmacotherapy</i> , 1996, 30, 736-739.	0.9	6
43	Use of Confidence Intervals and Sample Size Calculations in Health Economic Studies. <i>Annals of Pharmacotherapy</i> , 1995, 29, 719-725.	0.9	38
44	Drug Utilisation Studies as Tools in Health Economics. <i>Pharmacoeconomics</i> , 1994, 5, 299-312.	1.7	19
45	Allopurinol Hypersensitivity Syndrome: A Review. <i>Annals of Pharmacotherapy</i> , 1993, 27, 337-343.	0.9	311
46	Erythromycin-Induced Hypoacusis: 11 New Cases and Literature Review. <i>Annals of Pharmacotherapy</i> , 1993, 27, 950-955.	0.9	16
47	Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist. <i>Annals of Pharmacotherapy</i> , 1993, 27, 1126-1133.	0.9	76
48	Interferon Alfa-2a-Induced Impotence. <i>DICP: the Annals of Pharmacotherapy</i> , 1991, 25, 1397-1397.	0.2	6